Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled alic4e trial in 15 european countries

HIGHLIGHTS

• who: Xiao Li from the (UNIVERSITY) have published the research work: Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries, in the Journal: (JOURNAL)
• what: The authors aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics using data collected in an open-label multi-season randomised controlled trial of oseltamivir in 15 European countries.

SUMMARY

Members of the ­ALIC . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.